C3 glomerulopathy and eculizumab: a report on four paediatric cases


Eculizumab may be used to treat C3-glomerulopathy (C3G), a rare but severe glomerular disease. Patients 1, 2 and 3 were diagnosed with nephritic syndrome with alternative complement pathway activation (low C3, C3Nef-positive) and C3G at the age of 9, 13 and 12 years, respectively. Treatment with eculizumab normalized proteinuria within 1, 2 and 7 months… (More)
DOI: 10.1007/s00467-017-3619-2

2 Figures and Tables


  • Presentations referencing similar topics